Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

Study Background and Disease Burden

Migraine is a prevalent neurological disorder characterized by recurrent moderate to severe headache episodes, frequently accompanied by nausea, photophobia, and phonophobia. Episodic migraine, defined as having fewer than 15 headache days monthly, affects millions worldwide, significantly impairing quality of life and productivity. Despite the availability of some preventive therapies, many patients experience inadequate relief or intolerable side effects. Angiotensin receptor blockers (ARBs), particularly candesartan, have emerged as potential migraine preventives due to their vascular and neuroprotective properties. However, evidence from large well-controlled trials has been limited. This phase 2 trial aimed to comprehensively evaluate the efficacy, safety, and tolerability of candesartan in episodic migraine prevention, addressing a notable gap in migraine therapeutics.

Study Design